Evaluation of the clinical efficacy of regorafenib (Belvango) and its treatment indications for different cancers

Regorafenib is an oral multi-target tyrosine kinase inhibitor that can simultaneously inhibit tumor angiogenesis, tumor microenvironment signaling pathways and multiple targets related to cancer cell proliferation, such asVEGFR, KIT, RET and RAF, etc. Its unique multi-target mechanism of action enables it to show significant efficacy in the treatment of a variety of advanced solid tumors, making it an important treatment option for patients with refractory tumors.

In patients with advanced metastatic colorectal cancer (mCRC), regorafenib is often used in patients who have progressed on standard chemotherapy regimens (eg, fluorouracil, oxaliplatin, irinotecan). Clinical studies have shown that regorafenib can significantly prolong patients' progression-free survival (PFS) and overall survival (OS). For example, the CORRECT study showed that compared with placebo, the median OS in the regorafenib treatment group was about 1.4 months, with a median PFS extension of about 0.7 months, with a manageable safety profile.

Regofenib has also shown efficacy in advanced gastrointestinal stromal tumors (GIST), particularly in patients who have failed imatinib and sunitinib. Clinical trials have shown that regorafenib can extend patients' progression-free survival and provide a certain disease control rate. In addition, in the first-line or second-line treatment of advanced hepatocellular carcinoma (HCC), regorafenib can delay disease progression and improve median overall survival, providing a new treatment option for HCC patients who are inoperable or unable to tolerate other targeted drugs.

The efficacy evaluation of regorafenib usually includes indicators such as tumor response rate, disease control rate, progression-free survival and overall survival. Although its single-agent efficacy may be limited, regorafenib can still provide important clinical benefits for patients who are refractory or have failed multiple lines of therapy. In clinical application, the efficacy and safety should be reasonably evaluated based on the patient's overall condition, previous treatment history and tolerance, and common adverse reactions, such as hand-foot syndrome, hypertension, fatigue and abnormal liver function, should be closely monitored to ensure the continuity and safety of treatment.

Reference link:https://www.drugs.com